NuCana (NASDAQ:NCNA) Shares Down 0.5% – Time to Sell?

Posted by Brenda Bartman on Jun 6th, 2026

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA – Get Free Report) dropped 0.5% during mid-day trading on Thursday . The company traded as low as $2.01 and last traded at $2.02. Approximately 41,854 shares were traded during trading, a decline of 3% from the average daily volume of 43,071 shares. The stock had previously closed at $2.03.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NuCana presently has a consensus rating of “Sell”.

Read Our Latest Analysis on NuCana

NuCana Trading Down 3.5%

The company has a market cap of $8.11 million, a PE ratio of -0.65 and a beta of 2.18. The firm’s 50-day simple moving average is $2.00 and its two-hundred day simple moving average is $2.61.

NuCana (NASDAQ:NCNA – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.64) by $1.39.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC raised its stake in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA – Free Report) by 210.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 10,000 shares of the company’s stock after buying an additional 6,774 shares during the period. FNY Investment Advisers LLC owned about 33.33% of NuCana worth $36,000 at the end of the most recent quarter. 44.00% of the stock is currently owned by institutional investors and hedge funds.

NuCana Company Profile

(Get Free Report)

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.